Evidence map›Paper›PMID 36960342›Full record

ArticleFrontiers in medicine2023

Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images.

Alexander Partin, Thomas Brettin, Yitan Zhu, James M Dolezal, Sara Kochanny, Alexander T Pearson, Maulik Shukla, Yvonne A Evrard, James H Doroshow, Rick L Stevens

Open access · goldFull text read
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Alexander PartinDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, United States.
Thomas BrettinDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, United States.
Yitan ZhuDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, United States.
James M DolezalSection of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, United States.
Sara KochannySection of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, United States.
Alexander T PearsonSection of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, United States.
Maulik ShuklaDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, United States.
Yvonne A EvrardFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States.
James H DoroshowDivision of Cancer Therapeutics and Diagnosis, National Cancer Institute, Bethesda, MD, United States.
Rick L StevensDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, United States.
Argonne National Laboratory · USUniversity of Chicago Medical Center · USLeidos Biomedical Research Inc. (United States)National Cancer Institute · US

Funding

BASIC RESEARCH TRAINING IN MEDICAL ONCOLOGYT32CA009566 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 1987 to 2026
$10.5M
Phase 01 Clinical TrialsZIABC011078 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$9.0M
NCI NIH HHS T32 CA009566
6 · The paper itself

Abstract

Patient-derived xenografts (PDXs) are an appealing platform for preclinical drug studies. A primary challenge in modeling drug response prediction (DRP) with PDXs and neural networks (NNs) is the limited number of drug response samples. We investigate multimodal neural network (MM-Net) and data augmentation for DRP in PDXs. The MM-Net learns to predict response using drug descriptors, gene expressions (GE), and histology whole-slide images (WSIs). We explore whether combining WSIs with GE improves predictions as compared with models that use GE alone. We propose two data augmentation methods which allow us training multimodal and unimodal NNs without changing architectures with a single larger dataset: 1) combine single-drug and drug-pair treatments by homogenizing drug representations, and 2) augment drug-pairs which doubles the sample size of all drug-pair samples. Unimodal NNs which use GE are compared to assess the contribution of data augmentation. The NN that uses the original and the augmented drug-pair treatments as well as single-drug treatments outperforms NNs that ignore either the augmented drug-pairs or the single-drug treatments. In assessing the multimodal learning based on the MCC metric, MM-Net outperforms all the baselines. Our results show that data augmentation and integration of histology images with GE can improve prediction performance of drug response in PDXs.

Indexed as

data augmentationdrug response predictiongene expressionhistology whole-slide imagesmultimodal deep learningpatient-derived xenograft (PDX)preclinical drug studies

Identifiers

PMID36960342
PMCPMC10027779
OpenAlexW4323364054

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.